NASDAQ:PROK ProKidney Q4 2024 Earnings Results & Report $1.44 -0.14 (-8.60%) As of 03:40 PM Eastern This is a fair market value price provided by Massive. Learn more. ProKidney missed analyst earnings expectations in its Q4 2024 results, released March 17, 2025. The company reported EPS of -$0.17 versus the -$0.14 consensus estimate, while revenue was $0.08 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 17, 2025TimeBefore Market OpensConference Call9:30 AM ET ProKidney EPS ResultsActual EPS-$0.17Consensus EPS -$0.14Beat/MissMissed by -$0.03One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersProKidney Revenue ResultsActual Revenue$0.08 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsProKidney's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) ProKidney Q4 2024 Earnings FAQ Did ProKidney beat earnings estimates for Q4 2024? ProKidney (NASDAQ:PROK) reported earnings of -$0.17 per share for Q4 2024, missing the consensus estimate of -$0.14. The report was announced on Monday, March 17, 2025. What was ProKidney's revenue for Q4 2024? ProKidney reported revenue of $0.08 million for Q4 2024. When is ProKidney's next earnings date? ProKidney's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for ProKidney on the company's earnings history page. ProKidney Earnings HeadlinesProKidney (NASDAQ:PROK) Shares Down 6% - Here's WhyOctober 14 at 2:21 AM | americanbankingnews.comProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026October 2, 2026 | markets.businessinsider.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026October 2, 2026 | globenewswire.comProKidney consensus price target increased by 22.40% to MX$116.87September 29, 2026 | msn.comProKidney (PROK) Stock Forecast & Price TargetSeptember 19, 2026 | investing.comSee More ProKidney Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ProKidney? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProKidney and other key companies, straight to your email. Email Address About ProKidneyProKidney (NASDAQ:PROK) (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney disease. The company’s approach is designed to support kidney function and potentially delay or reduce the need for dialysis or kidney transplantation in patients with progressive kidney disease. Its lead product candidate, rilparencel, is an autologous renal cell therapy made from a patient’s own kidney cells. The cells are processed and administered back into the patient’s kidneys, where they are intended to promote the production of proteins and other factors associated with kidney health. ProKidney is evaluating rilparencel in clinical studies involving patients with diabetic kidney disease and other forms of chronic kidney disease. ProKidney was founded in 2015 and became a publicly traded company in 2022 through a business combination with Social Capital Suvretta Holdings Corp. III. The company is headquartered in Winston-Salem, North Carolina, and its clinical development activities have primarily focused on patients and research sites in the United States.View ProKidney ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
